<?xml version="1.0" encoding="UTF-8" ?>
<rss version="2.0">
<channel>


<title>aktiencheck.de - Forum - Eyenovia Inc</title>
<link>http://www.aktiencheck.de</link>
<description>aktiencheck.de</description>
<language></language>
<copyright>aktiencheck.de</copyright>
<lastBuildDate>Sat, 25 Apr 2026 05:55:22 +0200</lastBuildDate>
<ttl>2</ttl>








<item>
<title>Eyenovia (WKN: A2N6DV)</title>
<link>http://www.aktiencheck.de/forum/Eyenovia_WKN_A2N6DV-A40ZAN-t579713</link>
<guid>http://www.aktiencheck.de/forum/Eyenovia_WKN_A2N6DV-A40ZAN-t579713</guid>
<description>Wiedervorlage bei der FDA akzeptiert ..., "The agency has assigned the resubmitted NDA a standard review with a Prescription Drug User Fee Act (PDUFA) target action date of May 8, 2023. The FDA also indicated that it is currently not planning to hold an advisory committee meeting to discuss the application."

Werde heute verkaufen und wieder bei knapp über einem Dollar einsteigen in 2023 ... viel zu lange hier gewartet und mir einigen Gewinn entgehen lassen.Eyenovia Announces FDA Acceptance of New Drug Application for MydCombi™ for In-Office Pupil Dilation | Eyenovia Inc.https://ir.eyenovia. [&lt;a href=&#034;http://www.aktiencheck.de/forum/Eyenovia_WKN_A2N6DV-A40ZAN-t579713&#034;&gt;mehr&lt;/a&gt;]</description>
</item>



</channel>
</rss>







